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Abstract: Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and 
B) in the brain are associated with clinically signiﬁ  cant antidepressant effects. In the US, the 
selegiline transdermal system (STS; EMSAM) is the ﬁ  rst antidepressant transdermal delivery 
system to receive Food and Drug Administration (FDA) approved labeling for the treatment of 
major depressive disorder (MDD). Currently, the use of orally administered MAO inhibitor anti-
depressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events 
(eg, acute hypertension and headache, also known as the “cheese reaction”) when combined 
with dietary tyramine. The selegiline transdermal system is the only MAOI available in the 
US for the treatment of MDD that does not require dietary restriction at the clinically effective 
dose of 6 mg/24 hours. Delivery of selegiline transdermally (EMSAM®) bypasses hepatic ﬁ  rst 
pass metabolism, thereby avoiding signiﬁ  cant inhibition of gastrointestinal and hepatic MAO-A 
activity (ie, reduced risk of tyramine-provoked events) while still providing sufﬁ  cient levels 
of selegiline in the brain to produce an antidepressant effect. At dosages of 6–12 mg/24 hours, 
EMSAM has been shown to improve symptoms of depression, have good tolerability, and have 
high rates of medication adherence. However, at higher doses of EMSAM (ie, 9 mg/24 hours 
or more), dietary restriction of tyramine intake is recommended. The introduction of EMSAM 
overcomes many of the safety concerns afﬁ  liated with the conventional oral MAO inhibitors 
and EMSAM may be considered another strategy for the treatment of MDD, especially in 
patients who cannot tolerate oral antidepressants, are poorly adherent, who present with atypical 
depressive symptoms, or have failed other antidepressants.
Keywords: selegiline, transdermal, EMSAM®, major depressive disorder, monoamine oxidase 
inhibitor
Introduction
Monoamine oxidase inhibitors (MAOIs) have experienced cyclical popularity. Initially 
used for the treatment of tuberculosis, these agents became recognized and used for 
antidepressant effects in the late 1950s (Goldberg 1964). However, in the early 1960s, 
published case reports described an acute hypertensive reaction (tyramine-provoked 
event), sometimes fatal, between MAOIs and foods containing tyramine (Blackwell 
1963; Blackwell and Mabbitt 1965; Blackwell et al 1967). These reports prompted 
signiﬁ  cant publicity concerning food and drug interactions with this class of drugs and, 
subsequently, prompted a decline in MAOI use. Use of MAOIs further diminished due 
to replacement by use of tricyclic antidepressants (TCAs) in the 1970s and non-TCAs 
in the 1980s precisely because of the problems with dietary restrictions and safety 
concerns. Currently, conventional MAOIs continue to be used in various neurologic 
(eg, headache) (Evans et al 2006) and psychiatric (eg, anxiety and mood) conditions, 
albeit not widely. MAOIs have been demonstrated to be superior to TCAs in the 
treatment of atypical depression (ie, depression marked by symptoms of hypersomnia, 
hyperphagia, severe lack of energy) (Quitkin et al 1988) and are considered effective 
alternatives for patients with TCA refractory depression (Roose et al 1986; McGrath Neuropsychiatric Disease and Treatment 2007:3(5) 528
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et al 1987). MAOIs may also be advantageous for treatment 
of depression in the elderly (Georgotas et al 1986), panic 
disorder (Liebowitz et al 1990), and phobias (Liebowitz et al 
1992). Nevertheless, the use of this very effective class of 
antidepressants is diminished by concerns about safety and 
drug interactions (Clary et al 1990).
Currently, selective serotonin reuptake inhibitors (SSRIs) 
are considered ﬁ  rst line in the treatment of major depressive 
disorder (MDD); however, MAOIs still have a role in the 
treatment of mood disorders. The American Psychiatric 
Association recommends that MAOIs may be beneﬁ  cial 
in patients with atypical depression and patients who have 
failed trials with other antidepressants (APA 2000). MAOIs 
currently available in the US with a Food and Drug Admin-
istration (FDA) approved labeling for depression include: 
phenelzine (Nardil®, Pﬁ  zer, Inc, New York, NY, USA), 
tranylcypromine (Parnate®, GlaxoSmithKline, Research 
Triangle Park, NC, USA ), isocarboxazid (Marplan®, Oxford 
Pharmaceutical Services, Inc, Totowa, NJ, USA), and most 
recently, selegiline transdermal system (STS; EMSAM®, 
Bristol-Myers Squibb, Princeton, NJ, USA). Interest in the 
use of MAOIs for MDD has re-emerged in part by results from 
the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) trial (McGrath et al 2006). Treatment refractory 
patients were randomly assigned to open-label treatment 
with either tranylcypromine monotherapy or combination 
of mirtazapine and venlafaxine. Both groups demonstrated 
similar remission rates and time to remission although the 
tranylcylpromine group had higher attrition rates due to 
tolerability issues (McGrath et al 2006).
MAOI pharmacology for depression
Monoamine oxidases are ubiquitous enzymes that exist 
in mammalian tissues in two genetically distinct forms, 
referred to as MAO-A and MAO-B (Youdim and Finberg 
1983). The physiologic role of MAO is to catalyze the 
biotransformation of a variety of arylalkylamine neu-
rotransmitters, such as dopamine, norepinephrine, and 
serotonin as well as to detoxify biogenic amines, such as 
tyramine (McDaniel 1986). The overall reaction involves 
oxidative deamination and can be characterized as: 
RCH2NH2 + H2O + O2 → RCHO + NH3 + H2O2. Each 
isoenzyme demonstrates distinct substrate specificity, 
inhibitor selectivity, and a unique tissue distribution. 
MAO-A is primarily responsible for degrading serotonin 
and norepinephrine, as well as exogenous monoamines such 
as tyramine. MAO-B is primarily responsible for degrading 
dopamine. Both MAO isoenzymes are present in tissues of 
the brain, gastrointestinal tract, and liver; however, MAO-A 
predominates in the gastrointestinal and hepatic tissues and 
MAO-B in brain tissue (Saura Marti et al 1990).
MAO-A inhibition is required for clinical improvement 
in depressed patients following the administration of oral or 
transdermal selegiline. Experimental studies have demon-
strated that the antidepressant-like effect of selegiline requires 
greater than 70% inhibition of MAO-A activity (Gordon 
et al 1999). Additionally, the metabolites of selegiline (eg, 
levo-amphetamine derivatives) do not signiﬁ  cantly contribute 
to the parent drug’s antidepressant activity nor does phenyl-
ethylamine (PEA), an amphetamine-like compound which 
accumulates when MAO-B is inhibited. In contrast to the 
potent dextro-amphetamine molecule, levo-amphetamine is 
several-fold less potent in elicitation of central nervous sys-
tem effects and thus not likely to exert a clinically signiﬁ  cant 
behavioral effect (Hoffman and Lefkowitz 1996).
Oral selegiline for depression
Selegiline is an irreversible inhibitor of MAO enzymes. 
Approved in the US as an adjunctive treatment in Parkinson’s 
disease (PD), orally administered selegiline (ie, conventional 
selegiline [Eldepryl®, Somerset Pharmaceuticals, Inc, Tampa, 
FL, USA]), up to 10 mg/day and orally disintegrating selegi-
line [Zelapar®, Valeant Pharmaceuticals International, Costa 
Mesa, CA, USA] up to 2.5 mg/day), is speciﬁ  c for MAO-B 
and generally devoid of clinically signiﬁ  cant antidepressant 
activity, as well as the potential for a tyramine-provoked event. 
However, at high oral dosages of selegiline, the speciﬁ  city 
for MAO-B is lost and non-selective inhibition of MAO (ie, 
MAO-A and MAO-B) confers antidepressant effects with the 
attendant risk of a tyramine-provoked event.
At oral doses between 30–60 mg/day (3–6 times greater 
than that used in the treatment of PD), selegiline has been 
studied for depression in several clinical studies and found 
to be effective. At these doses, oral selegiline signiﬁ  cantly 
inhibits MAO-A and MAO-B in the peripheral and cen-
tral tissues. However, because selectivity for MAO-B is 
lost (at doses exceeding 20 mg/day), the attendant risk 
of developing a tyramine-provoked event is increased (Schulz 
et al 1989). In a small double-blind, randomized, crossover 
study with placebo, treatment-resistant elderly patients who 
received oral selegiline 60 mg/day for 3 weeks had sig-
niﬁ  cant improvements in the Hamilton Depression Rating 
Scale 17-item (HAM-D-17) score (15.4 ± 9.2 vs 24.6 ± 6.4, 
p   0.01), the Global Depression score (5.8 ± 2.7 vs 7.5 ± 2.3, 
p = 0.05), and the Brief Psychiatric Rating Scale (p = 0.01 for 
18- and 28-item scores) (Sunderland et al 1994). In another Neuropsychiatric Disease and Treatment 2007:3(5) 529
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double-blind, placebo-controlled study [n = 44], a mean 
dose of 30 mg/day of selegiline was found to be superior 
to placebo in reducing the HAM-D mean score (41% vs 
10%, respectively) and produced a positive response rate 
of 50% in those receiving selegiline compared with 13.6% 
in placebo (Mann et al 1989). All patients followed a low-
tyramine diet and the incidence of adverse events, including 
cardiovascular effects, did not differ between the selegiline 
and placebo groups.
Selegiline transdermal system
Pharmacology overview
Selegiline transdermal system (STS) was designed to treat 
MDD and overcome the dietary safety concerns that exist 
with the conventional oral MAOIs. The STS provides 
stable and continuous drug delivery over a 24-hour period 
(Somerset Pharmaceuticals 2006). The STS allows the drug 
to be delivered directly into the systemic circulation rather 
than through the intestinal wall or the liver, thereby allow-
ing selegiline to bypass hepatic ﬁ  rst pass metabolism. This 
pharmacokinetic feature of the transdermal delivery system 
provides sufﬁ  cient concentrations of selegiline in the central 
nervous system to inhibit both MAO-A and B for an antide-
pressant effect while minimizing inhibition of gastrointestinal 
and hepatic MAO-A activity and the risk of developing a 
tyramine-provoked reaction (Mawhinney et al 2003). The 
transdermal patches are composed of three layers (backing, 
adhesive containing the drug, and the release liner) and con-
tain 1 mg of selegiline per cm2 (Somerset Pharmaceuticals 
2006). Upon administration, approximately 25%–30% of the 
STS drug content is delivered, in a steady and continuous 
manner, over 24 hours; this is equivalent to approximately 
0.3 mg selegiline per cm2 over 24 hours. The mean half-life 
of selegiline is approximately 1.5 hours (Mahmood 1997). 
Since the drug is an irreversible (suicide) enzyme inhibitor, 
the drug elimination half-life is less relevant and the dura-
tion of MAO enzyme inhibition is dependent on the rate 
of de novo enzyme synthesis. Selegiline is metabolized by 
hepatic CYP450 isoenzymes to 3 principal metabolites, 
N-desmethylselegiline, levo-methamphetamine, and levo-
amphetamine (Shin 1997) (Figure 1). When compared with 
oral administration at equivalent doses, transdermal admin-
istration of selegiline to elderly subjects resulted in a 50-fold 
greater systemic exposure to parent drug and a 70% reduction 
in exposure to metabolites (Barrett et al 1996). Selegiline is 
not highly protein bound (89%) and transdermally delivered 
selegiline has 75% bioavailability (Somerset Pharmaceuti-
cals 2006) compared with approximately 10% for the oral 
conventional formulation (Mahmood 1997). There is no 
accumulation of the drug in the skin.
Availability, dosing, and 
administration
EMSAM is available in 3 doses, 6 mg/24 hours (20 mg/20 cm2), 
9 mg/24 hours (30 mg/30 cm2), and 12 mg/24 hours (40 
mg/40 cm2). Treatment should be initiated at the lowest dose 
of 6 mg/24 hours (Somerset Pharmaceuticals 2006). There 
are no dose-response studies but if indicated, the dose can be 
increased by 3 mg/24 hours every 2 weeks, up to a maximum 
dose of 12 mg/24 hours. The patch should be applied approxi-
mately at the same time every day and dosage adjustment 
is not required in patients with moderate liver impairment 
(Child-Pugh classiﬁ  cations of A or B) although there is no 
data regarding severe liver impairment. EMSAM does not 
require dose adjustment in mild, moderate, or severe renal 
impairment. In elderly patients, a target maintenance dose 
of 6 mg/24 hours is recommended.
The patch should be applied to dry, intact skin on the 
upper torso (below the neck and above the waist), upper 
thigh, or the outer surface of the upper arm once every 
24 hours. It should be noted that while patients should 
replace the patch daily, they may still derive therapeu-
tic beneﬁ  t if the patch is left on the skin for more than 
24 hours. EMSAM continues to be released from the patch 
and this may be a potential advantage in patients who forget 
to replace the patch daily. Due to application site reactions, 
patients should be advised to rotate the application sites to 
avoid re-application to the same site on consecutive days. 
Patients should wash their hands before and after patch 
application.
Adverse effects
The most common side effects of the STS include application 
site reaction, headache, diarrhea, dyspepsia, insomnia, dry 
mouth, pharyngitis, and sinusitis (Somerset Pharmaceuti-
cals 2006). In placebo-controlled trials, 7.1% of patients 
discontinued EMSAM treatment versus 3.6% of patients 
receiving placebo; application site reaction was the only 
adverse event contributing to discontinuation of treatment. In 
EMSAM-treated patients, application site reactions occurred 
in 24% compared with 12% in those receiving placebo. 
Orthostatic hypotension (9.8% EMSAM, 6.7% placebo) was 
also reported and was dose-related. Elderly patients were 
more likely to experience orthostatic hypotension. In both 
short- and long-term clinical studies, a lack of signiﬁ  cant 
weight gain and sexual dysfunction was observed with STS Neuropsychiatric Disease and Treatment 2007:3(5) 530
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treatment. This is notable since oral antidepressants (ie, 
MAOIs, TCAs, SSRIs) are associated with clinically sig-
niﬁ  cant effects in these areas (Rabkin et al 1984). Although 
these observations need to be validated in post-marketing 
studies, STS may prove to be a viable alternative in patients 
who experience these symptoms or who prefer medications 
without these effects.
Food interactions
In 1963, a pharmacist communicated observations to an 
English psychiatrist named Blackwell. The patient in each 
observation was the pharmacist’s wife and involved a reac-
tion after co-ingestion of tranylcypromine with cheese. 
The ﬁ  rst reaction was described as: “After cheese on toast; 
within a few minutes face ﬂ  ushed, felt very ill; head and 
heart pounded most violently, and perspiration was running 
down her neck. She vomited several times…[and] after about 
three hours she was normal other than a severe headache….” 
(Blackwell et al 1967). The reaction also occurred in a sub-
sequent ingestion (ie, rechallenge) of cheese on toast with 
co-ingestion of tranylcypromine. The pharmacist wrote: 
“Could there be a link between the effects and the amino acids 
of the cheese? No effects are caused by butter or milk…If 
cheese is indeed the factor, it could perhaps explain the spo-
radic nature of incidence of the side-effect.” (Blackwell et al 
1967). Over 40 years later, the MAOI-tyramine interaction is 
one of the most publicized drug interactions in the medical 
literature. In individuals treated with conventional oral 
MAOIs, ingestion of small amounts of tyramine (eg, 8 mg) 
can result in the “cheese reaction”.
The typical features of a MAOI-associated tyramine-
provoked event are occipital headache radiating forward, 
nausea, palpitations, and tachycardia which occur acutely and 
subside within hours. Other features include dilated pupils, 
hypertension, neck stiffness, photophobia, reﬂ  ex bradycardia 
with chest tightness, and sweating.
Tyramine challenge studies
Using an oral tyramine pressor test, as little as 8 mg of tyramine 
is sufﬁ  cient to cause an increase in systolic blood pressure of 
30 mmHg in 50% of tranylcypromine-treated subjects (Bieck 
and Antonin 1988). Cooper notes that prior to the recognition 
of the need for dietary restrictions, up to 25% of MAOI-treated 
patients experienced a tyramine-provoked event (eg, acute 
hypertension, headache) with serious sequelae such as stroke 
or death occurring in up to a quarter of the affected patients 
(Cooper 1989). However, this potentially severe side effect 
could have been largely avoided by the implementation of 
simple dietary precautions. Unfortunately, at that time, sus-
picion and fear burgeoned, and both the seriousness and the 
frequency of risk were dramatically inﬂ  ated. This was a major 
factor in the subsequent general disuse of the irreversible 
MAOIs. In contemporary clinical practice, dietary restrictions 
are less of a concern, although concerns do persist.
Studies indicate that the actual risk of a clinically sig-
niﬁ  cant tyramine-provoked event with the STS is rare and 
Figure 1 Biotransformation of selegiline.
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may be considered negligible (Azzaro et al 2006; Blob 
et al 2007). Healthy male subjects were challenged with 
encapsulated tyramine HCl under various conditions (Table 
1) (Azzaro et al 2006). In one group of 12 subjects treated 
with STS 6 mg/24 hours for 9 days and then 33 days (with 
a 3 month washout between treatments), the mean tyramine 
pressor doses (ie, dose of tyramine HCl required to achieve 
a sustained increase above baseline in systolic blood pres-
sure (SBP) of  30 mmHg for 3 consecutive readings), in the 
absence of food, at 9 and 33 days were 292 mg and 204 mg, 
respectively (p   0.05). Although the difference is statisti-
cally signiﬁ  cant, no clinically meaningful differences in safety 
were noted. An ingestion of tyramine 200 mg or more, derived 
from a single meal, is highly unlikely and approximately 6 
times more than that contained in a tyramine-rich meal and 
20 times greater than that contained in a normal meal (Da 
Prada et al 1988; Shulman et al 1989; Walker et al 1996). 
One study examined the tyramine content of high-tyramine 
meals (5 course) from 6 different restaurants and found 
that the tyramine content ranged from approximately 10 to 
36 mg per meal (Da Prada et al 1988). Cheeses made from 
pasteurized milk contain very low amounts of tyramine (less 
than 50 mg/kg) (Da Prada et al 1988) and a whole pizza with 
a double-cheese topping has been reported to contain less 
than 1 mg tyramine (Shulman and Walker 1999).
A study was performed to assess for differences in 
tyramine pressor dose between STS and conventional oral 
selegiline treatment. Following a crossover design with a 
washout period of 3 months between active treatments, the 
pressor effects of tyramine following treatment with STS was 
compared with that obtained with oral selegiline (10 mg/day). 
The mean tyramine pressor doses for oral selegiline and STS 
6 mg/24 hours were not signiﬁ  cantly different (385 mg and 
338 mg, respectively, p = 0.19), indicating that the dietary 
safety of STS 6 mg/24 hours is similar to conventional oral 
selegiline 10 mg/day.
The STS 6 mg/24 hours has a much wider margin 
of dietary safety than conventional oral tranylcypro-
mine. A study was performed to assess for differences in 
tyramine pressor dose between STS 6 mg/24 hours and oral 
Table 1 Tyramine pressor doses (TPD) obtained in subjects administered the selegiline transdermal system, oral conventional selegi-
line 5 mg twice daily, and tranylcypromine sulfate 30 mg/daya
 N  Duration  Baseline  tyramine  On-treatment  tyramine
    of treatment  pressor doseb, mg  pressor doseb, mg
   (days)  (mean  ± SEM)  (mean ± SEM)
Changes in TPD after extended dosing
STS 6 mg/24 h  12  9  508 ± 29   292 ± 23c
STS 6 mg/24 h  12  33  483 ± 40   204 ± 25c,d
STS 12 mg/24 h  11  33  568 ± 27  95 ± 23c,e
STS 12 mg/24 h  11  63  568 ± 27  72 ± 15c,e
STS 12 mg/24 h  11  93  568 ± 27  88 ± 18c,e
Changes in TPD before and after a meal
STS 12 mg/24 h Fasted  8  93  606 ± 24  64 ± 10c
STS 12 mg/24 h Fed  8  96  606 ± 24  172 ± 32c,f
TPD differences between STS and oral selegilineg
STS 6 mg/24 h  13  9  550 ± 30   338 ± 31c
Oral selegiline (5 mg bid)  13  9  550 ± 28   385 ± 36c,h
TPD differences between STS and tranylcypromine
STS 6 mg/24 h  10  10  480 ± 28   270 ± 26c
Tranylcypromine 30 mg/daya 9  8  400  ± 24   10 ± 0c,i
aTranylcypromine sulfate administered orally as 20 mg in the morning and 10 mg the afternoon.
bTyramine pressor dose = dose of tyramine HCl required to achieve a sustained increase above baseline in systolic blood pressure (SBP) of  30 mmHg for 3 consecutive 
readings. Following tyramine challenge, blood pressure was monitored at 5-minute intervals from 0 to 2 hours and at 15-minute intervals from 2 to 6 hours. If the SBP 
exceeded the baseline. measurement by  25 mmHg, the interval for monitoring was decreased to 3-minute intervals.
cp   0.001 compared with baseline.
dp   0.05 compared with crossed-over subjects administered STS 6 mg/24 h.
ep   0.005 compared with 6 mg/24 h for 33 days.
fp   0.005 compared with fasted.
gA 3-month washout between STS and oral selegiline was imposed.
hp = 0.19 compared with STS 6 mg/ 24 hours.
ip   0.01 compared with crossed-over subjects administered STS 6 mg/24 h.
Abbreviations: STS, selegiline transdermal system.
Derived from Tables II, III and IV from Azzaro et al (2006).Neuropsychiatric Disease and Treatment 2007:3(5) 532
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tranylcypromine sulfate 30 mg/day (Azzaro et al 2006). 
Following a crossover design with a washout period of 8 
weeks between active treatments, the pressor effects of 
tyramine following treatment with STS was compared with 
that obtained with tranylcypromine. The mean tyramine 
pressor dose for STS 6 mg/24 hours was 270 mg, whereas 
all tranylcypromine-treated subjects experienced a pressor 
response following an initial tyramine HCl dose of 10 mg and 
this difference was statistically signiﬁ  cant (p   0.0001).
To determine the effects of a higher STS dose, 
12 mg/24 hours, on tyramine pressor responses, 11 subjects 
were treated and tyramine pressor doses were assessed after 
33, 63, and 93 days of treatment. Results, listed in Table 
1, reveal that at higher STS doses, the mean tyramine dose 
required to elicit a pressor response is signiﬁ  cantly decreased. 
With the STS 12 mg/24 hours-treated group, the tyramine 
pressor doses ranged from 25 to 200 mg. Thus the dietary 
safety margin is dose dependent. Within the treatment 
duration of 33–93 days, difference in the mean tyramine 
pressor dose were not statistically signiﬁ  cant (p = 0.36), 
suggesting that a pharmacodynamic steady state (tyramine 
pressor sensitivity) is achieved by 33 days of treatment.
When co-administered with food, the risk of tyra-
mine-provoked events appears to be minimal even at 
12 mg/24 hours. Tyramine pressor responses were assessed 
in fasted and fed states. In STS 12 mg/24 hours-treated 
subjects, the presence of food signiﬁ  cantly increased, by 
approximately 3-fold, the mean tyramine dose required to 
elicit a clinically signiﬁ  cant pressor response (Table 1).
Realistically, it is not reasonably possible to consume suf-
ﬁ  cient amounts of tyramine in the form of cheeses to induce 
a clinically signiﬁ  cant tyramine response in STS-treated 
patients. In an open-label study, 16 healthy adult male subjects 
were enrolled to receive STS 6 mg/24 hours for 13 days (Blob 
et al 2007). At baseline and on the ﬁ  nal day, subjects ingested 
aged cheeses for breakfast (equivalent to approximately 100 
mg tyramine content) and for dinner (equivalent to approxi-
mately 320 mg tyramine content). Cardiovascular response 
was monitored after the meals and no clinically signiﬁ  cant 
changes in vital signs (eg, SBP) were observed. Of note, 4 of 
the 16 (25%) enrolled subjects were unable to consume the 
protocol deﬁ  ned amount of cheese during baseline testing.
In summary, the results of several tyramine challenge 
studies conﬁ  rm that treatment with STS is associated with 
a wide margin of safety compared with the non-selective 
MAOI antidepressants in terms of dietary interactions 
(Azzaro et al 2006; Blob et al 2007). The data from these 
tyramine challenge studies should allay concerns regarding 
treatment with STS and dietary interactions. However, it 
should be noted that the tyramine challenge studies enrolled 
male subjects, and sex-based differences in tyramine 
response have been observed, with females tending to show 
greater pressor sensitivity than males (Reimann et al 1992). 
However, in the STS clinical studies (vide post), the majority 
of patients were female and dietary tyramine was allowed in 
all but one of these studies.
Despite the data supporting the dietary safety of EMSAM, 
the manufacturer does recommend that when initiating therapy 
with 9 mg/24 hours or 12 mg/24 hours, tyramine-containing 
foods should be avoided (Table 2). Furthermore, the dietary 
restrictions are advised for at least 2 weeks after either dose 
reduction (eg, from 9 mg or 12 mg/24 hours to 6 mg/24 hours) 
or discontinuation of the 9 mg or 12 mg/24 hour patches. 
Patients should be educated on the signs and symptoms of 
the “cheese reaction” (eg, headache occurring after ingestion 
of certain food and beverages).
Drug interactions
Drug interaction precautions are recommended for the STS 
(Table 3), similar to those recommended for high dose oral 
selegiline and other non-selective MAOIs. Most of the 
restrictions for STS, however, are extrapolated from known 
experience with or theoretical concerns about drug interaction 
sequelae involving other MAOIs, rather than speciﬁ  c data 
from oral selegiline or STS drug interaction studies. The 
actual risk of various drug interactions with MAOIs is not 
always clearly established. Given the unique pharmacokinetic 
proﬁ  le of STS (in which transdermally administered selegi-
line bypasses the gut and liver), studies speciﬁ  cally investi-
gating drug interactions with STS are warranted.
Although the EMSAM product labeling states that the 
drug is contraindicated with sympathomimetic amines 
(due to risk of hypertensive crisis), the combination of an 
MAOI with a stimulant has been used safely in depression. 
A review of the recent literature revealed no documented 
reports of clinically signiﬁ  cant hypertensive events or fatali-
ties occurring when the stimulant was cautiously added to 
a MAOI (Feinberg 2004). Additionally, other studies have 
found no signiﬁ  cant adverse effects in patients receiving 
STS together with cocaine (Houtsmuller et al 2004) or 
pseudoephedrine (Azzaro et al 2007a). However, an increase 
in SBP (without clinical symptoms) with combination STS 
6 mg/24 hours and phenylpropanolamine has been reported 
(Azzaro et al 2007a).
In vitro experiments have identiﬁ  ed CYP2B6-, CYP2C9-, 
and CYP3A isoenzymes as having a signiﬁ  cant role in the Neuropsychiatric Disease and Treatment 2007:3(5) 533
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metabolism of selegiline. Other isoenzymes such as CYP1A2-, 
CYP2A6-, CYP2C8-, CYP2D6-, and CYP2C19 also may 
be involved (Taavitsainen et al 2000; Hidestrand et al 
2001; Kamada et al 2002; Salonen et al 2003; Azzaro et al 
2007b).
Plasma concentrations of selegiline following steady-state 
treatment with STS are in the range of 0.01 μM to 0.08 μM. 
In vitro, selegiline causes a concentration-dependent inhibi-
tion of several CYP450 isoenzymes but at concentrations 
of 10 μM or greater. As this is several orders of magnitude 
greater than the observed plasma concentrations at clinically 
relevant doses of STS, signiﬁ  cant inhibitory effects on the bio-
transformation of CYP450 substrates is not to be expected. 
Experimental studies fail to show signiﬁ  cant drug–drug 
interactions between STS and psychotropic drugs such as 
olanzapine, risperidone, and alprazolam, that are CYP1A2, 
2D6 and 3A4 substrates, respectively (Azzaro et al 2007b). 
This may be an important feature as a majority of patients 
diagnosed with MDD also meet criteria for an additional 
psychiatric diagnosis (Kessler et al 2003) and may be 
co-prescribed other psychotropic medications that are 
CYP450 substrates.
There is, however, a pharmacokinetic interaction with 
carbamazepine in which increased levels of selegiline and 
its metabolites were seen with concomitant administration 
of EMSAM (Somerset Pharmaceuticals 2006) and therefore 
the use is contraindicated. The plasma concentrations of 
selegiline were increased approximately two-fold in patients 
who received carbamazepine 400 mg/day for 14 days. In 
addition, because molecular scaffolds of carbamazepine and 
oxcarbazepine are tricyclic, the use of these two agents is 
contraindicated with EMSAM due to theoretical concerns 
of serotonin syndrome.
Prior to initiating EMSAM, contraindicated drugs 
(Table 3) should be discontinued and the equivalent of at 
least 5 half-lives should elapse before initiating EMSAM. For 
example, due to a risk of serotonin toxicity, several weeks 
should elapse after discontinuing antidepressants (5 weeks 
for ﬂ  uoxetine and 2 weeks for other antidepressants) before 
starting therapy with EMSAM. Conversely, if EMSAM is 
discontinued, at least 2 weeks should elapse before initiating 
therapy with a drug that is contraindicated.
Clinical efﬁ  cacy
The clinical efﬁ  cacy of transdermal selegiline monotherapy 
has been established in 4 published double-blind, placebo-
controlled studies (Table 4) (Bodkin and Amsterdam 
2002; Amsterdam 2003; Feiger et al 2006; Amsterdam and 
Bodkin 2006). The criteria for all three short-term efﬁ  cacy 
studies were the presence of single or recurrent unipolar 
major depression in out-patients with a HAM-D-17 score 
of  20. In the ﬁ  rst published multi-center study, 177 adult 
patients aged 18–65 years with MDD were randomized to 
receive 20 cm2 selegiline transdermal patch (equivalent to 
6 mg/24 hours) or placebo (Bodkin and Amsterdam 2002). 
In this ﬁ  xed-dose study, selegiline showed signiﬁ  cant reduc-
tion in the mean HAM-D-17 (46%, p = 0.01) and HAM-
D-28 (52%, p = 0.004) scores compared with placebo as 
well as the Montgomery-Asberg Depression Rating Scale 
(MADRS) (79%, p = 0.005). These reductions on all three 
scales were observed as early as week 1. There was also 
Table 2 Foods and beverages that contain tyraminea
Aged and fermented meats
Sausages and salamis
Pickled herring
Spoiled or improperly stored meat, poultry, and ﬁ  sh
Spoiled or improperly stored animal livers
Broad bean pods
Aged cheeses
Beers that have not been pasteurized (ie, tap beer)
Red wine
Concentrated yeast extract
Sauerkraut
Soybean products (including soy sauce and tofu; excluding soy milk)
Over-the-counter products containing tyramine
aTyramine content varies widely within each food or beverage category.
Derived from Shulman et al (1989).
Table 3 Medications to avoid with the selegiline transdermal 
system
Amphetaminesa
Bupropiona
Buspirone
Carbamazapinea and oxcarbazepinea
Cold products with vasoconstricting properties (eg, pseudoephedrine,
phenylephrine, phenylpropanolamine, ephedrine)a
Cyclobenzaprinea
Dextromethorphana
Linezolid
Meperidine,a methadone,a propoxyphene,a and tramadola
Mirtazapinea
Monoamine oxidase inhibitors (eg, rasagiline, oral selegiline, isocarboxa-
zid, phenelzine, tranylcypromine)a
Selective serotonin reuptake inhibitors (eg, ﬂ  uoxetine, paroxetine, 
sertraline)a
Serotonin norepinephrine reuptake inhibitors (eg, venlafaxine, 
duloxetine)a
St. John’s worta
Tricyclic antidepressants (eg, amitriptyline, imipramine)a
aContraindicated as per EMSAM product labeling.
Derived from Somerset Pharmaceuticals (2006), Taylor et al (2006).Neuropsychiatric Disease and Treatment 2007:3(5) 534
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signiﬁ  cant improvement on the Clinical Global Impres-
sion (CGI) severity (p = 0.02) and global improvement 
(p = 0.007) scales in the selegiline group versus the placebo 
group. The efﬁ  cacy analyses were conducted in the intent-
to-treat study group using the last observation carried for-
ward (LOCF) analysis and included all patients who were 
randomized to treatment with selegiline and had at least one 
evaluation. At the end of the study, 152 subjects (86%) had 
completed the trial and 9 of these patients dropped out of 
the study due to adverse events (4 patients in selegiline, 5 
patients with placebo). The only reported adverse events that 
were signiﬁ  cantly different between selegiline and placebo 
were skin and application site reactions. Selegiline-treated 
patients exhibited a signiﬁ  cantly improved sexual function 
compared with placebo-treated patients (F = 4.78, df = 1, 
145, p = 0.03). Additionally, during the close monitoring 
of blood pressure, subjects who received selegiline had 
greater mean change in orthostatic blood pressure (–2.3 
mmHg) versus those who received placebo (–0.8 mmHg) 
(F = 15.75, df = 1, 170, p = 0.0001), although these changes 
were not considered clinically meaningful. Since all patients 
followed a tyramine-restricted diet, the study was not able 
to establish safety with a non-restricted diet.
In a second multi-center, 8 week study, 289 adult 
patients with moderate to severe MDD were randomized in a 
double-blind fashion to either selegiline transdermal system 
20 mg/20 cm2 (6 mg/24 hours) or placebo (Amsterdam 2003). 
In contrast to the former study, patients in this study were 
not required to adhere to a tyramine-restricted diet. Patients, 
however, were instructed to check with the study investiga-
tor prior to initiating medications that have been historically 
known to interact with monoamine oxidase inhibitors (eg, 
over-the-counter cold preparations, narcotic and non-narcotic 
analgesics, antidepressants, antihypertensives). Most of the 
patients had recurrent major depressive episode and the mean 
HAM-D-17 scores at baseline were similar for selegiline and 
placebo groups. At the end of the 8 week study using the 
LOCF analysis, patients who received selegiline transdermal 
had signiﬁ  cantly lower MADRS scores at week 4 (p = 0.024) 
and the effect persisted until week 8 (p = 0.001). The STS 
was also associated with lower mean HAM-D-28 scores but 
the effect was not observed until week 8. The discontinuation 
rate due to adverse effects was low, 6.7% and 5.3% in the 
selegiline and placebo groups, respectively, and application 
site reaction was the only adverse event that differed sig-
niﬁ  cantly between the two groups (31.5% for selegiline vs 
15.1% for placebo, p = 0.001). Reductions in the mean SBP 
and DBP were observed in the STS group compared with the 
placebo group (–0.5 ± 10.7 mmHg vs –0.8 ± 11.7 mmHg for 
systolic BP; –0.5 ± 7.7 mmHg vs –1.0 ± 7.5 mmHg for DBP, 
respectively) although the difference was not statistically 
signiﬁ  cant. Differences in other cardiovascular measures (eg, 
heart rate, electrocardiogram) were not observed.
In a third study enrolling 265 patients with MDD, 
patients were randomized, in a double-blind manner, to 
STS or placebo (Feiger et al 2006). This was an 8 week, 
Table 4 Summary of published studies
Study Method  N  Duration  Primary  efﬁ  cacy  Adherence  Tyramine
    (% females)    outcome measures  rate  restricted diet
Bodkin and  Fixed dose  177  6 weeks  ♦HAM-D-17, -28  94%  Yes
Amsterdam (2002)  (6 mg)  (60%)    ♦MADRS (average)
       ♦CGI
Amsterdam (2003)  Fixed dose  301  8 weeks  ♦MADRS   98% No
 (6  mg)  (64%)    ♦HAM-D-17, -28
       ♦CGI-S, CGI-C
Feiger et al (2006)  Flexible (6 mg,  265  8 weeks  Mean   STS: 96%  No
  9 mg, 12 mg)  (61%)    change in  Placebo: 89%
       ♦HAM-D-28
       ♦MADRS
       ♦IDS-SR
Amsterdam and  Fixed dose  322  10 weeks   In double-blind  Open label:  No
Bodkin (2006)  (6 mg)  (68.5%)  (open label)  phase  88.1%
     52  weeks  ♦HAM-D-28 Double-blind:
     (double-blind)  ♦MADRS STS:  84.2%
       ♦CGI-S Placebo:  89.6%
       ♦CGI-I
Abbreviations: CGI-S, Clinical Global Impression-Severity of Illness Scale; CGI-C, Clinical Global Impression-Change Scale; MADRS, Montgomery Asberg Depression 
Rating Scale; HAM-D-17, -28, 17 and 28 item Hamilton Depression Rating Scales; IDS-SR, Inventory of Depressive Symptomatology (Self-reported).Neuropsychiatric Disease and Treatment 2007:3(5) 535
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ﬂ  exible-dose study utilizing STS doses of 6 mg/24 hours 
to 12 mg/24 hours and did not require dietary restriction 
of tyramine. Patients were also limited to use of con-
comitant medications that may interact with selegiline, 
although sleep agents such as chloral hydrate, zolpidem, 
and antihistamines were allowed. At the end of the 8 week 
study, 206 patients completed the study with approxi-
mately 22% drop out rate due to primary reasons of “lost 
to follow up” and “adverse event.” Most of the patients 
were Caucasian female with recurrent major depression, 
similarly to the two previous studies. During the study 
period, 88% and 96% of patients received 9 mg/24 hours 
or the equivalent-sized placebo patch, respectively. Fur-
thermore, 48% of patients received 12 mg/24 hours of 
selegiline versus 63% of patients in the placebo group. 
Patients who received STS had significant improve-
ment in the primary efficacy measure, HAM-D-28, 
compared with patients who received placebo (p = 0.03) 
at weeks 5 and 8. Other significant differences were 
observed for the MADRS (p = 0.02) and the Inventory 
for Depressive Symptomatology-Self Rated (IDS-SR) 
(p = 0.03) at week 8 and the HAM-D (6-item Bech) at weeks 
5 and 8 (p   0.01). Although there was a difference in the 
HAM-D-17 scores between the treatment groups, the 
difference was not statistically significant. Overall, 
80% and 74% of patients in the STS and the placebo 
groups had an adverse event and the most frequent 
event observed was application-site reaction (40% and 
20%, respectively). No episodes of hypertensive crises 
were observed although insomnia was also a frequent 
occurrence with the STS group (30%) compared to the 
placebo group (14%). There was a higher incidence of 
sedative hypnotic use in the STS group (14%) compared 
with the placebo group (8%). The STS appeared to be 
well-tolerated at the higher doses since approximately 
half of the patients received the higher doses of 9 and 
12 mg/24 hours.
The most recent study was a ﬁ  xed-dose relapse preven-
tion study of 322 patients that lasted 1 year (Amsterdam 
and Bodkin 2006). All patients received STS 6 mg/24 
hours for 10 weeks in open-label fashion. Responders 
(those with HAM-D-17 scores of  10 in the ﬁ  nal 2 weeks 
of the lead-in) were randomized in a double-blind manner 
to continue STS or placebo for 52 weeks. The primary 
efﬁ  cacy measure was the proportion of patients achiev-
ing relapse based on a combination of HAM-D-17 score 
 14, CGI severity of illness score  3 (with at least a 2 
point increase from double-blind baseline), and meeting 
the DSM-IV criteria for MDD. STS-treated patients expe-
rienced signiﬁ  cantly less relapse (16.8%) than placebo-
treated patients (30.7%) (p = 0.0025) at the end of the study. 
In those who did experience a relapse, the time to relapse 
was longer in the STS group (p = 0.0048). The most 
notable adverse effect in the STS group was application 
site reaction, and no cases of hypertensive reaction were 
reported. Adherence was high in both the selegiline and 
placebo groups (84.2% and 89.6% respectively) and dis-
continuation rates due to adverse event were higher for the 
STS group (13.2% vs 6.1%, respectively). It should also 
be noted that 56% of patients who were randomized were 
prematurely discontinued from the study for reasons other 
than meeting relapse criteria.
In summary, STS 6 mg/24 hours is effective as monother-
apy for MDD. Only one of the four studies assessed dosages 
exceeding 6 mg/24 hours; therefore, it is uncertain whether 
higher doses correspond to better efﬁ  cacy. The majority of 
patients in the clinical studies were females (Table 4), which 
is consistent with the higher prevalence of depression in 
this population. In addition, three of the four studies did not 
require a tyramine-restricted diet and the most frequently 
reported adverse effect was application site reaction.
Precautions and contraindications
Patients who are prescribed EMSAM should be counseled 
on the issue of dietary safety and potential drug interactions. 
Patients receiving EMSAM should be warned against under-
going elective surgery that requires general anesthesia or 
sympathomimetic vasoconstricting agents. EMSAM should 
be discontinued at least 10-days prior to the surgery, if nec-
essary. Patients with pheochromocytoma should not receive 
EMSAM. Prolonged exposure to external heat sources such 
as electric blankets, heaters or direct sunlight may potentially 
enhance dermal absorption of selegiline from the patch matrix 
(Somerset Pharmaceuticals 2006).
Although EMSAM is not indicated for use in children 
or adolescents, a black box warning for suicidality in this 
population exists for EMSAM and stems from literature on 
SSRIs and other antidepressants (not EMSAM) suggesting 
increased suicidality. Patients and clinicians should moni-
tor for signs of suicidality, worsening of symptoms, and/or 
changes in behavior, especially at the initiation of treatment 
and during dosage changes. Interpretation of the actual risk 
of suicidality in children and adolescents seen in studies is 
complex and has resulted in controversy over the decision 
to treat or not to treat this population. While analysis of 
all antidepressant trials in pediatric patients found that the Neuropsychiatric Disease and Treatment 2007:3(5) 536
Lee and Chen
risk of suicidal behaviors was approximately twice as high 
in those who received an antidepressant versus those who 
received placebo (Simon 2006), others argue that the beneﬁ  ts 
of antidepressants outweigh the risk of suicide or suicide 
attempt (Bridge et al 2007).
There are no well-controlled studies in pregnant women 
with EMSAM (Pregnancy Category C). The potential beneﬁ  ts 
of using EMSAM in the mother should be weighed against 
the risk to the fetus. It is unknown whether selegiline is 
excreted in breast milk in humans. In animal studies, the 
levels of selegiline and metabolites in milk were approxi-
mately 15 and 5 times the steady-state levels in maternal 
plasma (Somerset Pharmaceuticals 2006).
Place in therapy, future directions
The efﬁ  cacy of the MAOI class in treatment-resistant patients 
and patients with atypical depression may provide a rationale 
for the use of selegiline transdermal system given its favor-
able tolerability proﬁ  le and recent data supporting improved 
dietary and drug interaction safety. Transdermal selegiline 
may also be potentially advantageous in patients who are not 
able to tolerate oral medications due to systemic side effects 
or who prefer a transdermal dosage formulation. While 
adherence rates for taking oral medications daily compared 
with a daily patch is debatable, adherence to antidepressant 
medications remains a signiﬁ  cant challenge to ensuring 
appropriate treatment of depression and preventing relapse 
(Lin et al 2003). In a recent study, adherence rates for anti-
depressant medications for more than 90 days after initiation 
of medication was less than 30% (Olfson et al 2006). When 
evaluating the impact of inadequate treatment of depression 
on relapse rates, quality of life and economic burden, any 
measure that may increase adherence rates to antidepressants 
should be explored. In the published studies for EMSAM, 
the adherence rate to the novel delivery system ranged from 
84% to  98%. Although post-marketing experience may 
have varying effects on adherence, the potential beneﬁ  t of 
a patch versus an oral medication should be a therapeutic 
consideration. As mentioned previously, the added beneﬁ  t 
of the residual drug remaining in the patch for more than 
24 hours may offer a slight advantage to oral medications.
Transdermal selegiline may potentially play a role in con-
ditions other than MDD. A small placebo-controlled study 
found that STS was modestly efﬁ  cacious in patients with 
HIV-associated cognitive impairment (Sacktor et al 2000). 
In addition, there is interest in studying the effects of STS 
in the treatment of cocaine abuse (Houtsmuller et al 2004) 
and nicotine dependence (ClinicalTrials 2007).
Conclusion
The selegiline transdermal system (STS; EMSAM), is the 
only MAOI available in the US for the treatment of MDD 
that does not require dietary restriction at the clinically effec-
tive dose of 6 mg/24 hours. The STS may also play a role 
in the treatment of atypical depression, treatment resistant 
MDD, and anxiety disorders. The unique delivery system 
also may provide an advantage for patients unable to tolerate 
the systemic effects of oral antidepressants or who prefer an 
alternative dosage formulation. Overall, the STS appears to 
be well-tolerated with application site reactions as the most 
common adverse reaction and low rates of weight gain and 
sexual dysfunction. Additionally, the STS is associated with 
minimal CYP450 mediated drug–drug interactions.
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